Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 6967-6972

  Williams, Louise H ^a   Choong, David ^a   Johnson, Sandra A ^a   Campbell, Ian G ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2;

ARTICLE; BREAST CANCER; CHROMOSOME 22Q; COLON CANCER; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE CLUSTER; GENE LOCUS; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METHYLATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION;

ALLELES; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 22; COLONIC NEOPLASMS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; VARIATION (GENETICS);

EID: 33845780616     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1770     Document Type: Article

References (26)

1. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
2. Vahteristo P, Bartkova J, Eerola H, et at. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71: 432-8.
3. CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-82.
4. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
5. de Jong MM, Nolte IM, Te Meerman GJ, et al. Colorectal cancer and the CHEK2 1100delC mutation. Genes Chromosomes Cancer 2005;43:377-82.
6. Bartkova J, Horejsi Z, Koed K, et at. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
7. Zhang P, Wang J, Gao W, et al. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004;3:14.
8. Tort F, Hernandez S, Bea S, et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 2002;100:4602-8.
9. Kato N, Fujimoto H, Yoda A, et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell Death Differ 2004;11:5153-61.
10. Reddy A, Yuille M, Sullivan A, et al. Analysis of CHK2 in vulval neoplasia. Br J Cancer 2002;86: 756-60.
11. Sullivan A, Yuille M, Repellin C, et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 2002;21:1316-24.
12. Campbell IG, Allen J, Eccles DM. Prohibitin 3′ untranslated region polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12: 1273-4.
13. Campbell IG, Choong D, Chenevix-Trench G. No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. Breast Cancer Res 2004;6:R366-71.
14. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
15. Kilpivaara O, Vahteristo P, Falck J, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004;111:543-7.
16. Staalesen V, Falck J, Geisler S, et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004;23:8535-44.
17. Tavor S, Takeuchi S, Tsukasaki K, et al. Analysis of the CHK2 gene in lymphoid malignancies. Leuk Lymphoma 2001;42:517-20.
18. Ingvarsson S, Sigbjornsdottir BI, Huiping C, et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 2002;4:R4.
19. Miller CW, Ikezoe T, Krug U, et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002;33:17-21.
20. Haruki N, Saito H, Tatematsu Y, et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000;60:4689-92.
21. Hofmann WK, Miller CW, Tsukasaki K, et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res 2001;25:333-8.
22. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006; 43:e34.
23. Cavener DR, Ray SC. Eukaryotic start and stop translation sites. Nucleic Acids Res 1991;19:3185-92.
24. Bird A. The essentials of DNA methylation. Cell 1992;70:5-8.
25. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005;26:2031-45.
26. Hashiguchi Y, Tsuda H, Inoue T, et al. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004;35: 165-75.